BioCentury
ARTICLE | Clinical News

Amikacin: Phase III ongoing

November 16, 2015 8:00 AM UTC

Insmed now expects to complete enrollment 6-12 months later than its initial expectation of by year end in the open-label, international Phase III CONVERT trial evaluating once-daily Arikayce in about...